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Abstract: Surgical resection of colorectal liver metastases is associated with greater survival compared 
with non-surgical treatment, and a meaningful possibility of cure. However, the majority of patients are not 
eligible for resection and may require other non-surgical interventions, such as liver-directed therapies, to be 
converted to surgical eligibility. Given the number of available therapies, a general framework is needed that 
outlines the specific roles of chemotherapy, surgery, and locoregional treatments [including selective internal 
radiation therapy (SIRT) with Y-90 microspheres]. Using a data-driven, modified Delphi process, an expert 
panel of surgical oncologists, transplant surgeons, and hepatopancreatobiliary (HPB) surgeons convened 
to create a comprehensive, evidence-based treatment algorithm that includes appropriate treatment 
options for patients stratified by their eligibility for surgical treatment. The group coined a novel, more 
inclusive phrase for targeted locoregional tumor treatment (a blanket term for resection, ablation, and other 
emerging locoregional treatments): local parenchymal tumor destruction therapy. The expert panel proposed 
new nomenclature for 3 distinct disease categories of liver-dominant metastatic colorectal cancer that is 
consistent with other tumor types: (I) surgically treatable (resectable); (II) surgically untreatable (borderline 
resectable); (III) advanced surgically untreatable (unresectable) disease. Patients may present at any point 
in the algorithm and move between categories depending on their response to therapy. The broad intent of 
therapy is to transition patients toward individualized treatments where possible, given the survival advantage 
that resection offers in the context of a comprehensive treatment plan. This article reviews what is known 
about the role of SIRT with Y-90 as neoadjuvant, definitive, or palliative therapy in these different clinical 
situations and provides insight into when treatment with SIRT with Y-90 may be appropriate and useful, 
organized into distinct treatment algorithm steps. 
Keywords: Metastatic colorectal cancer; selective internal radiation therapy (SIRT); yttrium-90; local 
parenchymal tumor destruction therapy; transarterial radioembolization
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Introduction
 
The liver is a common site of metastatic tumor development 
in patients with advanced colorectal cancer (CRC) (1); liver 
metastases are present in approximately 20–35% of patients 
with CRC at diagnosis and in up to 70% at death (1-3). 
The median survival of patients with untreated CRC liver 
metastases (CRCLM) after diagnosis is 6–12 months, with 
survival after 5 years being rare (4). Surgical resection of 
CRCLM has shown 5-year survival rates of approximately 
20–70% and should be the goal for eligible patients (5). 
Unfortunately, the majority (70–80%) of patients with liver-
dominant disease are not suitable candidates for resection 
due to technical reasons, severe comorbidities, or significant 
extrahepatic disease (1,5,6). The goal of current medical 
treatment for patients with borderline resectable CRCLM 
is to improve tumor response rates to maximize the 
potential for curative resection (7). However, for patients 
with chemorefractory CRCLM, there is no standard 
recommended treatment course (8).
Identifying patients with liver mCRC for appropriate 
treatment
Decisions relating to patient selection for specific treatment 
choices are critical in the management of mCRC (5) and 
include decisions about the type and duration of treatment (9). 
Treatment goals for patients with mCRC have been 
classified as curative intent (“resectable” or “operable”), 
potentially curative, non-curative with active treatment 
intent, and non-curative with palliative intent (i.e., best 
supportive care) (10,11). Choice of first-line therapy 
initiates the treatment sequence, leading to subsequent 
treatment decisions for next-line therapies, which depend 
on both the treatment goal and the molecular subtype of the 
tumor (11). The sequence of treatments is also important 
given the potential for recurrence requiring subsequent 
treatment with additional lines of therapy and the potential 
interaction between them (11). 
To confound these decisions,  the definit ion of 
resectability seems to differ in clinical practice, and patients 
with liver-dominant mCRC who are classified as having 
unresectable disease in one institution might be said to 
have resectable disease in another institution (12,13). 
Even among experienced surgeons, there is variability in 
decision-making, where some choose to resect while others 
are more conservative (7). When resectability of CRCLMs 
were examined by both colorectal and liver specialist 
teams, management decisions were divergent in almost 
half of patients (13). Thus, many patients with potentially 
resectable CRCLM are not being considered for potentially 
beneficial treatment by appropriate specialists (13). 
Patient evaluation by a clinically experienced liver surgeon 
is essential to ensure that resection is appropriately 
considered in each patient’s multidisciplinary treatment 
strategy (4,7,14). To provide a potentially curative option 
for patients with liver-limited, unresectable mCRC that 
cannot be resected until regression of tumors from critical 
structures, conversion strategies can be used to downsize 
and convert CRCLM to a resectable status (5,7). 
Current treatment options for CRCLM
Systemic chemotherapy has been shown to yield high 
tumor response rates that result in appreciable rates of 
conversion to resectability, including irinotecan-based 
or oxaliplatin-based regimens in combination with anti-
epidermal growth factor receptor (EGFR) inhibitors such 
as cetuximab, with rates being reported between 4% and 
60% for downsizing with chemotherapy alone (5,7,15-17). 
Posttreatment resectability has been associated with better 
overall survival (OS), which demonstrates the importance 
of conversion chemotherapy (12). In patients who are 
converted to resection with chemotherapy, 5-year survival 
can approach 30–50%, with 20% of patients alive 10 years 
after resection (17). Intra-arterial therapies may also be 
used to downsize metastases to allow resection, even in 
patients who have disease refractory to chemotherapy (18). 
New locoregional liver-directed therapies are emerging 
but have not yet become the standard of care in many 
practices (6). As metastatic tumors greater than 3 mm are 
supplied primarily by the hepatic artery (19), treatments 
administered via the hepatic arterial system enhance 
delivery of tumoricidal and embolizing agents to tumor 
tissue and may reduce significant hepatic and systemic 
toxicity (8,18,20). Such treatments include hepatic arterial 
infusion pump (HAIP) therapy, conventional transarterial 
chemoembolization (cTACE), drug-eluting bead transarterial 
chemoembolization (DEB-TACE), and selective internal 
radiation therapy (SIRT) with yttrium-90 (Y-90) [also called 
intra-arterial brachytherapy, transarterial radioembolization 
(TARE)] (8,21,22). With the diversity of available systemic 
and locoregional treatments for patients with mCRC, 
establishing an effective management approach may be 
challenging, in part due to a lack of comparative studies and 
differences in institutional practices (8,23). 
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SIRT is an arterially delivered brachytherapy that 
percutaneously delivers microspheres containing Y-90, a 
beta-emitting radionuclide, directly into the tumor via the 
hepatic artery (6). SIRT with Y-90 has been found to cause 
tumor necrosis and fibrosis and has effects on dystrophic 
calcifications and tumor vasculature (24). Evidence suggests 
that SIRT with Y-90 may improve treatment response in 
patients with chemorefractory mCRC (25) and in patients 
receiving 5-fluorouracil (5-FU) chemotherapy (26), and 
may also delay liver disease progression when administered 
as first-line therapy with chemotherapy (16). Furthermore, 
SIRT has been used as a tool to downsize select patients 
with CRCLM with increases in resectability (27) and actual 
resection rates that have ranged between 10% and 21% 
(15,16,28,29). However, most patients who receive SIRT 
with Y-90 present in the salvage setting, with extensive liver 
tumor load, reduced performance status, chemorefractory 
disease, and many prior chemotherapy cycles (30). In 
fact, these heavily treated patients are poor candidates 
for any type of therapy, often having disease that failed 
to respond to all other evidence-based treatments (31). 
Outside of broad guidelines provided by the US National 
Comprehensive Cancer Network (NCCN) and European 
Society for Medical Oncology (ESMO), the need for 
consensus remains for the specific roles of SIRT with Y-90 
for patients with CRCLM (32-34).
Need for evidence-based consensus for treatment 
Arterially directed catheter therapy and, in particular, SIRT 
with Y-90 microspheres, has been included in the ESMO 
and NCCN guidelines for the management of patients 
with mCRC (5,35). The NCCN guidelines recommend 
SIRT with Y-90 for treatment of mCRC in highly selected 
patients with chemotherapy-resistant/-refractory disease 
and with predominant hepatic metastases (Category 2A 
recommendation) (5) but requires further evidence to 
recommend a role for this treatment at earlier stages of 
mCRC (5). The ESMO guidelines recommend SIRT with 
Y-90 for patients with liver-limited disease that has failed 
the available chemotherapeutic options (Level II evidence, 
Grade B recommendation) and leaves room for potential 
earlier use as “consolidation treatment” (35). 
Despite the inclusion of intra-arterial therapies in these 
guidelines, consensus is needed among oncology specialists 
regarding the exact sequence involved in treating different 
stages of liver-dominant mCRC, particularly the specific 
roles of chemotherapy, surgery, and locoregional treatments 
(1,33). There is need for evidence-based, multidisciplinary 
consensus with respect to the specific role of SIRT with Y-90 
in the treatment of patients with varying degrees of liver-
dominant mCRC (32) as well as criteria for appropriate 
patient selection (36). 
To this end, a multi-step series of expert panels was 
convened with experienced practitioners, including surgical 
oncologists, transplant surgeons, and hepatopancreatobiliary 
(HPB) surgeons, to review current clinical evidence on 
the role of SIRT with Y-90 in the treatment landscape of 
mCRC. The result was a data-driven treatment algorithm 
based on the surgical resectability/tumor destruction 
status of patients, with the goal of moving patients toward 
eligibility for curative or disease-stabilizing therapy. The 
expert panels sought to investigate practical considerations, 
grade the evidence, and provide guidance on key 
considerations in the management of different clinical 
situations for patients with liver-dominant mCRC. This 
paper describes the development process of the proposed 
treatment algorithms, which included a systematic literature 
review followed by successive modified Delphi–based expert 
panels. The evidence-supported treatment algorithms focus 
on key considerations of mCRC treatment regarding the 
role of SIRT with Y-90.
Methods
Study design 
This evidence-based treatment algorithm was developed 
by a multidisciplinary expert panel of surgical oncologists, 
transplant surgeons, and HPB surgeons with extensive 
experience in treating mCRC. To develop the algorithm, a 
multi-step modified Delphi process was conducted, which 
provides a structured method of group communication to 
facilitate the aggregation of expert opinions and reach an 
agreement on complex issues (37). This process involved 
multiple stages between October 2018 and March 2019 
(Figure 1). First, a Core Expert Panel (N=8) met at 2 live 
meetings, as well as several webinars, and corresponded 
through email. 
The Core Expert Panel had 2 main goals. Firstly, it 
aimed to define distinct disease categories for patients with 
liver-dominant mCRC stratified by surgical treatability. 
Secondly, it aimed to create a treatment algorithm 
that detailed evidence-supported recommendations on 
appropriate treatment options for patients at various degrees 
of eligibility for surgical treatment, with an emphasis on 
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Figure 1 Multi-step modified Delphi process.
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SurgOnc (7); Transplant (4); HPB (6) 
Live Peer Discussion Workgroup  
(N=19)  









Broad scope literature search and review of the 
evidence by Core Expert Panel members to inform 
treatment decisions
Collaboration to define disease terms and 
treatment categories in line with evidence, with 
development of preliminary treatment algorithms
Peers appraise terminology and algorithm, 
examining supporting evidence quality via a 
structured online feedback form
Group conference to establish joint agreement on 
data-driven algorithm decision points
Algorithm refinement
Algorithm refinement




when SIRT with Y-90 would be appropriate. 
A blinded, broad-scope literature review was conducted 
to find publications on the role of SIRT with Y-90 in 
patients with mCRC (Figure 2). Eligible studies included 
systematic reviews and meta-analyses, randomized 
controlled trials (RCTs), phase I and II trials, prospective 
and retrospective cohort studies, case series, and consensus 
guidelines. Excluded publication types included non-
systematic reviews, single case reports, those involving only 
non-CRCs or primary liver tumors, and studies published 
before 2009. Levels of evidence were assigned based on 
study type according to criteria from the Oxford Centre 
for Evidence-Based Medicine (38). Articles were selected 
based on eligibly criteria and content relevant to the review. 
In addition to any published data analyzing the role of 
SIRT with Y-90 in mCRC, several specific themes were of 
interest because they were relevant to the specific intent 
to use SIRT with Y-90 to help move patients to surgical 
therapy. These included studies that discussed the role of 
SIRT with Y-90 in converting borderline resectable tumors 
to resectable status, inducing contralateral hypertrophy, 
treating small metastases completely, and treating disease 
while testing tumor biology with chemotherapy. After this 
review, 30 papers were deemed eligible and relevant and 
were included. Core Expert Panel members were given 
the primary literature to perform a detailed review of the 
evidence.
Based on the evidence, the Core Expert Panel developed 
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Figure 2 Literature review on the role of selective internal radiation therapy (SIRT) with Y-90 in patients with metastatic colorectal cancer (mCRC).
151 publications identified 
through database  
(PubMed) searcha
162 publications, after duplicates  
removed, assessed for eligibility
30 publications included in analysis
99 publications fit inclusion criteria and screened for relevance 
• Level 1a – Systematic Reviews (7) and Meta-Analyses (6)
• Level 1b – Randomized Controlled Trials (RCTs) (7)
• Level 2b – Phase I and II Trials (5) and Prospective (2) and Retrospective (5) 
Cohort Studies
• Level 4 – Case Series (55)
• Level 5 – Consensus Guidelines (10)
• Honorable Mentions (2)
63 publications excluded due to ineligibility
• Non-systematic reviews
• Single case reports
• Studies on non-colorectal cancers
• Studies on primary liver tumors
• Studies published before 2009
69 publications excluded due to lack of 
relevance
11 publications identified 





a Search terms: 1) [resection] AND [colorectal] AND [microspheres]; 2) [resection] AND [colorectal] AND [radioembolization]; 3) [resection]  
AND [colorectal] AND [brachytherapy]*; 4) [resection] AND [colorectal] AND [SIRT]*; 5) [SIRT] AND [downsizing]*; 6) [radioembolization] 
AND [downsizing]*; 7) [brachytherapy] AND [downsizing]*; 8) [SIRT] AND [downstaging]*; 9) [radioembolization] AND [downstaging]*; 10)  
[brachytherapy] AND [downstaging]*; 11) [downsizing] AND [colorectal] AND [metastatic]*; 12) [Yttrium-90] AND [mCRC]*  
*using filter for Publication dates from 2000-present
the preliminary algorithm (Step 1), provided critical review, 
and finalized the algorithm structure. The Core Expert 
Panel reviewed and approved the preliminary version of 
the algorithm. Ratings for the strength of evidence were 
provided with each treatment step. 
The algorithm and supporting evidence levels were 
then scrutinized by a larger Virtual Peer Panel (N=17) 
to create a modified algorithm (Step 2) in which key 
issues with decision points were identified. Based on 
the peer review, revisions were made to the draft to 
clarify treatment steps for clinical practice. A second 
in-person discussion workgroup meeting with a Live 
Peer Discussion Workgroup (N=19) was conducted to 
discuss these issues and further refine the algorithm. 
These treatment steps were refined and modified until 
agreement was reached to create a finalized algorithm 
(Step 3). If no consensus was achieved, the alternative 
views of the group were noted and are described herein. 
The group focused on creating a cohesive map for 
treating patients with mCRC, with an emphasis on the 
algorithm steps and their relative order. Attention was 
placed on arriving at a consensus about the overarching 
algorithm instead of explicitly measuring the degree 
of agreement on each individual step. Many individual 
treatment steps within the algorithm were based on 
already-established recommendations from NCCN 
and ESMO guidelines, referenced where appropriate. 
Evidence supporting all individual steps was added, 
including the levels of evidence of each study.
Results
Terminology for locoregional treatments
During discussion of terminology, the Core Expert Panel 
found that the terms ablation and resection excluded the 
use of other locoregional treatments, and determined a 
need for a more concise term to refer to tumor ablation or 
destruction technologies that are intended for complete 
local control that would otherwise be equivalent to resection 
(39-41). A more inclusive term for targeted locoregional 
tumor treatment, local parenchymal tumor destruction therapy, 
is a blanket term for both resection and ablation as well as 
other emerging locoregional treatments. This term leaves 
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room for the integration of future novel tumor therapies 
into the therapeutic armamentarium for patients with 
mCRC.
Treatment categories
When considering treatment approaches for different 
patient types, treatment goals are different depending on 
the status of the patient. The Core Expert Panel identified 
3 main disease categories for patients with liver-dominant 
mCRC stratified by surgical treatability and stipulated the 
general treatment goals for each group (Figure 3):
(I) Surgically treatable liver-dominant (resectable) 
mCRC: patients who are eligible for surgical 
treatment (curative intent);
(II) Surgically untreatable liver-dominant (borderline 
resectable) mCRC: patients who may be eligible for 
surgical treatment but are currently untreatable due to 
oncologic or technical factors and could be potentially 
converted to resectable status;
(III) Advanced surgically untreatable liver-dominant 
(unresectable) mCRC: patients who are not amenable 
to surgical treatment at the time of entry into the 
algorithm.
Of note, the use of this terminology for categories of 
surgical treatability mirrors treatment categories used in 
pancreatic cancer classification (42), for which the goal is to 
identify patients who would benefit from surgery by dividing 
patients into 3 similar treatment categories (42). They also 
echo the general views across the field of mCRC treatment, 
where it is understood that patients with CRCLM can 
generally be classified into resectable, potentially resectable/
convertible, and unresectable groups (5,23). Broad 
definitions of each disease category are outlined below and 
are meant to be used as rough parameters to choose the 
most appropriate treatment. When evaluating individual 
patients for treatment, physicians should consider not only 
disease-related factors such as extent of intrahepatic disease, 
presence/extent of extrahepatic disease, timing of metastatic 
diagnosis (synchronous versus metachronous), and disease 
biology, but also patient-related variables such as age, 
comorbidities, preferences, and expectations (23). 
Based on the categories of disease, the Core Expert 
Panel created a distinct treatment algorithm for each 
group, taking into account the unique considerations 
associated with each stage of disease. Each algorithm is a 
distinct entity. An overarching framework of the treatment 
algorithm is provided in Figure 4. Patients can enter the 
algorithm at any point and move vertically or laterally, 
depending on treatment response. The overarching goal 
Surgically Treatable Liver-Dominant  
(Resectable) mCRC
Surgically Untreatable Liver-Dominant  
(Borderline Resectable) mCRC
Advanced Surgically Untreatable  
Liver-Dominant (Unresectable) mCRC
Definition
• Primary colorectal tumor metastatic to the 
liver
• Candidate for local parenchymal tumor 
destruction therapy of liver metastases 
(eg, resection/ablation/other locoregional 
treatment)
• No untreatable extrahepatic sites of 
disease
• Likelihood of achieving complete resection 
of all evident disease with negative 
surgical margins
• Adequate liver reserve/anticipated FLR
Treatment goal
• Local parenchymal tumor destruction 
therapy (eg, resection/ablation) are 
focused on the curative intent of surgery 
(intent to clear all disease)
Definition
• Not amenable to local parenchymal tumor 
destruction therapy of liver metastases (eg, 
resection/ablation)
Treatment goal
• Focus on disease palliation
Definition
• Liver-dominant but surgically untreatable 
disease due to:
- Involvement of critical structures that 
impede local parenchymal tumor 
destruction therapy (eg, resection/
ablation/other locoregional treatment) 
unless regression is accomplished
- Inadequate liver reserve/anticipated 
FLR
- Anticipated R1 or worse margin status 
(tumor margin <1 mm)
- Heavy pretreatment volume of disease 
(ie, presence of prior metastases that 
are no longer visible, likely due to 
systemic treatment, but still may be 
present)
Treatment goal
• Conversion to curable or potentially 
curable disease
• Long-term management strategy with 
potential for cure
Figure 3 Treatment categories. The Core Expert Panel developed 3 categories of patients with liver-dominant metastatic colorectal cancer 
(mCRC) stratified by surgical treatability. FLR, future liver remnant.
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Surgically untreatable  






Figure 4 Treatment algorithm framework. The Core Expert Panel developed a distinct treatment algorithm for each group based on 
surgical treatability. Patients enter at any point and move vertically or laterally depending on response to treatment. mCRC, metastatic 
colorectal cancer.
of treatment is to transition patients toward eligibility for 
curative interventions or to achieve prolonged disease-free 
intervals. 
Category 1: Surgically treatable liver-dominant 
(resectable) mCRC 
Patients with surgically treatable liver-dominant (resectable) 
mCRC have a primary colorectal tumor metastatic to the 
liver (5,35), no untreatable extrahepatic sites of disease (5), 
and adequate liver reserve (5,35). They must be candidates 
for local parenchymal tumor destruction therapy of liver 
metastases (5). In these patients, there is a likelihood of 
achieving complete resection of all evident disease with 
negative surgical margins (5,35). The goal of treatment 
is to clear all disease, whether through local parenchymal 
destruction therapy or other methods (5,35). 
The treatment of patients with surgically treatable liver-
dominant (resectable) mCRC is outlined in Figure 5 (5,35). 
Patients with minimal disease (oligometastases) may be, 
in some situations, appropriate candidates for immediate 
surgical treatment, whereas patients with more extensive 
disease (metachronous, poorly differentiated) may require 
neoadjuvant or adjuvant chemotherapy to test disease 
trajectory and/or downsize lesions before local parenchymal 
tumor destruction therapy (5,35). Patients with a resectable 
primary colon tumor and resectable synchronous metastases 
can be treated with a synchronous or staged resection of 
the liver with curative intent (or a combination of liver 
resection and/or local tumor destruction, where equivalent, 
for CRCLM) (5,35,43).
However, not all patients with technically resectable 
liver-limited metastases will ultimately benefit from surgery, 
with approximately half developing widespread systemic 
disease within 3 years after resection (35). For some 
patients, neoadjuvant chemotherapy may be a better option 
than immediate surgery (35). An initial course (4–6 cycles) 
of systemic first-line chemotherapy is also a reasonable 
strategy for use in patients with resectable mCRC at high 
risk for recurrent disease, although evidence to support 
this approach is somewhat mixed (5,18,35). The expert 
panelists concurred that a neoadjuvant approach merits 
strong consideration in patients with any unfavorable factor, 
e.g., an extensive burden of liver disease, a short interval 
from primary diagnosis to the appearance of metastases, or 
extrahepatic disease (33,35). Response to chemotherapy is 
used by many investigators as a surrogate marker of tumor 
biologic behavior and may be used to select for hepatectomy 
in some patients (18). In fact, pathologic response to 
chemotherapy has been an important prognostic factor in 
patients who undergo resection for metastatic CRC (44). 
Radiographic assessment by CT and cross-sectional 
imaging may be performed often to assess for extrahepatic 
metastases and local recurrence (5,35). Magnetic resonance 
imaging (MRI) with hepatobiliary-specific contrast agents 
such as gadoxetate enhances detection of liver lesions (45). 
If size decrease or stable disease is achieved from treatment, 
combined or staged local parenchymal tumor destruction 
therapy may be used, depending on the tumor stage (5,35). 
Progression of disease can occur in different distinguishable 
metastatic patterns to aid treatment approach (46). Those 
who develop new metastases after chemotherapy can be 
transitioned to the treatment algorithm for surgically 
untreatable liver-dominant disease (borderline resectable) 
(5,35). The expert panelists agreed that those patients who 
have disease that progresses on first-line chemotherapy 
and experience lesion growth, but who remain surgically 
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Figure 5 Treatment algorithm for patients with surgically treatable liver-dominant (resectable) metastatic colorectal cancer (mCRC). 
ESMO, European Society for Medical Oncology; NCCN, National Comprehensive Cancer Network.
Surgically Treatable mCRC
Systemic first-line chemotherapy* (4-6 doses of FOLFOX or FOLFIRI)5,35
Radiographic Assessment5,35
Response
(decrease in size or stable disease)
Synchronous or staged tumor 
destruction of primary CRC and  
metastatic liver disease5,35
Adjuvant chemotherapy*5
*Consider perioperative chemotherapy and adjuvant chemotherapy in appropriate cases. Selected patients may be appropriate to go 
straight to surgery.
Supporting evidence
5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Colon Cancer. Version 4.2018. [NCCN Category 
2A Recommendation: Based on lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate]
35. Van Cutsem E, Cervantes A, Adam R, et al. Ann Oncol. 2016;27(8):1386-1422. [ESMO Level IV, grade B recommendation: 




Synchronous or staged 
tumor destruction 
of primary CRC and 
metastatic liver disease5,35
Surgically Untreatable  
Liver-Dominant  
(Borderline Resectable)  
mCRC35
New metastases
Synchronous or staged tumor 
destruction of primary CRC 
and metastatic liver disease5,35
treatable, could be considered for local parenchymal tumor 
destruction therapy (5,35). Ablation may provide acceptable 
oncologic outcomes for selected patients with small liver 
metastases that can be ablated with sufficient margins (5). 
Clinical studies have shown that 5- and 10-year OS rates 
for patients who have undergone ablation, for lesions that 
meet size criteria specifically, are comparable to reported 
survival rates after surgical resection (39,40). However, this 
similarity in survival rates is contingent upon the adherence 
to several factors, including tumor size as well as sufficient 
experience of the ablating professional (40,41). 
While utility of SIRT with Y-90 in surgically treatable 
liver-dominant mCRC is not well defined, it may have a 
role in selected patients. For example, for patients with a 
radiographic complete response to initial chemotherapy of 
a portion of lesions, SIRT with Y-90 has been described as 
a time-delaying and chemotherapy-sparing strategy to treat 
the remaining visible lesions with the goal of extending 
the time before subsequent chemotherapy is initiated 
(47,48). The potential for liver damage with chemotherapy 
emphasizes the importance of limiting the number of 
treatment cycles (9). SIRT with Y-90 may also be used to 
expedite treatment of metastases in chemotherapy-naïve 
patients who cannot receive timely chemotherapy due to 
inability to tolerate standard agents or limited access to 
certain healthcare services (32). 
Patients who progress on first-line chemotherapy with or 
without biologics have a worse overall prognosis than those 
who respond to treatment. This makes some clinicians 
hesitant to proceed directly to surgical treatment, even in 
patients with technically surgically treatable disease despite 
progression. The expert panelists discussed whether SIRT 
with Y-90 should be considered for use in this subset of 
patients. SIRT with Y-90 has been used as a complementary 
therapy in conjunction with second-line chemotherapy 
in patients with disease that failed to respond to first-line 
neoadjuvant chemotherapy (35,49,50). The SIRFLOX 
and FOXFIRE (SF/FFG) studies were conducted to 
investigate the early use of SIRT with Y-90 in patients 
with surgically untreatable mCRC and found that the 
addition of SIRT with Y-90 to FOLFOX-based first-line 
chemotherapy in patients with liver-dominant or liver-only 
mCRC did not improve progression-free survival (PFS), 
though results may have been biased by the enrollment 
of patients with significant extrahepatic disease (51). 
However, treatment with SIRT with Y-90 did significantly 
delay disease progression in the liver, which suggests that 
additional research is likely merited (16). In view of these 
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first indications of benefit for liver control, there is ample 
opportunity for additional investigation to strengthen the 
evidence (14,51). Further study is needed to determine 
whether this treatment can be clinically adopted, but based 
on data available, there is insufficient evidence to support 
a definitive role for the use of SIRT with Y-90 in patients 
with limited disease at this time (51). Additional clinical 
trials are required to determine if there is a role for SIRT 
with Y-90 in CRCLM with limited metastatic disease. (18). 
The expert panelists recognized that SIRT with Y-90 could 
be justified as first-line therapy in certain cases for selected 
patients with liver-dominant disease (16). 
Category 2: Surgically untreatable liver-dominant 
(borderline resectable) mCRC 
Patients in this category have liver-limited unresectable 
disease that, because of involvement of critical structures, 
cannot be resected unless regression is accomplished (5). 
Close proximity of the tumor to normal vital hepatic 
structures, such as the portal venous bifurcation, bile duct 
bifurcation, and/or hepatic veins, could potentially disqualify 
patients from surgery (52). An anticipated positive margin is 
an unfavorable feature that may make a patient not eligible 
for up-front resection. While there is no generally accepted 
definition of what constitutes a positive margin of resection, it 
has been defined as the presence of exposed tumor along the 
line of transection or the presence of tumor cells at the line 
of transection (<1 mm) detected by histologic examination 
(5,44). Shrinking the tumor and disengaging it from vital 
structures can increase the chance of becoming eligible for 
hepatic resection (52). An adequate future liver remnant 
(FLR) is imperative to avoid posthepatectomy liver failure 
and death (52); some patients may lack an adequate FLR and 
may require an intervention to convert to resectability (5). 
The goal of treatment is to convert the patient from a 
surgically untreatable to resectable status (5). This may 
often involve selecting a regimen most likely to elicit a rapid 
treatment response rather than a prolonged chemotherapy 
course that increases the risk of liver toxicity (5,9). 
The treatment of patients with surgically untreatable 
liver-dominant (borderline resectable) mCRC is outlined in 
Figure 6 (5,14,18,28,35,53-63). Preoperative chemotherapy 
may be used in appropriate cases in an attempt to downsize 
CRCLM and convert them to a resectable status (5). Patients 
with a borderline resectable status can be started on systemic 
chemotherapy, preferably with biologics, as the addition of 
biologics has been shown to increase treatment response (5,35). 
Radiographic assessment must be performed often to assess 
for extrahepatic metastases and local recurrence (5,33). To 
limit the development of hepatotoxicity, patients whose disease 
becomes surgically treatable can be considered to have moved 
laterally to the algorithm for patients with surgically treatable 
liver-dominant mCRC, where surgery (e.g., staged tumor 
destruction) can be considered as soon as possible (5,35). 
Patients who respond to treatment but whose liver 
reserves remain inadequate may undergo intervention to 
induce contralateral liver hypertrophy and then may be 
reassessed for surgical treatability (5,35). When the FLR 
is anticipated to be marginal, there are several options 
for improving liver reserves and inducing contralateral 
hypertrophy, to allow for safe major hepatectomy (64). 
These include portal vein embolization (PVE), SIRT with 
Y-90, 2-stage hepatectomy, and associating liver partition 
with portal vein ligation (PVL) for staged hepatectomy 
(ALPPS) (57,62,64). Among these, SIRT with Y-90 has 
the advantage of inducing contralateral hypertrophy while 
also exerting anti-tumoral effects (24,35,53,65). However, 
it is important to remember that hypertrophy induction 
after SIRT with Y-90 is slower than after PVE (65). To 
illustrate the FLR growth curve after treatment with SIRT 
with Y-90, FLR in one study increased to 23% within 1–3 
months after treatment, and then increased to 31–34% 
and 40–45% after 6 and 12 months, respectively (65). The 
anti-tumoral effect in the treated liver segments offered 
by SIRT with Y-90 allows for a longer interval to surgery 
and more time to develop contralateral hypertrophy. This 
prolonged waiting period has some benefits, including the 
possibility to assess for previously undetected contralateral 
metastases (65). If FLR hypertrophy is insufficient after 
SIRT with Y-90, a subsequent PVE/PVL treatment can be 
considered (65). After contralateral hypertrophy is achieved 
(4–6 weeks with PVE without interval chemotherapy, more 
than 6 weeks with chemotherapy, or 3 months after SIRT 
with Y-90), reassessment of liver regeneration and a second-
stage hepatectomy may be performed, possibly followed by 
additional chemotherapy (18,59,63,65). 
If metastatic lesions remain surgically untreatable, patients 
can be assessed to determine whether they require more 
chemotherapy or induction of contralateral hypertrophy 
(5,35). Patients who progress to advanced disease can be 
treated according to the algorithm for advanced surgically 
untreatable liver-dominant (unresectable) disease (5,35). 
SIRT with Y-90 has been used in patients with surgically 
untreatable (borderline resectable) mCRC who need a 
chemotherapy holiday or whose disease has failed available 
chemotherapeutic options as local disease control to 
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Figure 6 Treatment algorithm for patients with surgically untreatable liver-dominant (borderline resectable) metastatic colorectal cancer 
(mCRC). ALPPS, associating liver partition and portal vein ligation for staged hepatectomy; ESMO, European Society for Medical 
Oncology; FLR, future liver remnant; HAI, hepatic artery infusion; PVE, portal vein embolization; RCTs, randomized controlled trials; 
SIRT, selective internal radiation therapy.
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treat the dominant metastatic side of the liver, while 
chemotherapy is stopped, with the goal of improving liver 
PFS (5,35,36,48,61). As systemic treatment of mCRC 
results in altered tumor biology and consecutively acquired 
molecular resistance to therapy, chemotherapy-sparing 
or time-delaying strategies may be used to allow the 
disease to reappear for the purpose of further analysis (11). 
SIRT with Y-90 has been used to fill the gap in treatment as a 
consolidation therapy in patients after first-line chemotherapy 
(47,66). Even in patients who show radiographic complete 
response, it is understood that chemotherapy alone does not 
result in a pathologic “complete” response in 80% of patients 
(35,48,67). SIRT with Y-90 has also been used to obtain 
additional tumor reduction beyond chemotherapy as an 
adjunct to second-line or later treatment (14,24,28,48,58-61), 
as well as for the induction of contralateral hypertrophy in 
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patients with inadequate liver reserves (24,35,48,53-56). 
In patients with surgically untreatable (borderline 
resectable) mCRC, SIRT with Y-90 has been used to 
facilitate downsizing of liver-dominant mCRC tumors 
to convert selected patients to eligibility for surgical 
treatment (14,18) and as adjuvant therapy to decrease or 
stabilize tumor bulk before the patient undergoes systemic 
chemotherapy, lesion ablation, or liver resection (32). 
Category 3: Advanced surgically untreatable  
liver-dominant (unresectable) mCRC 
Patients with advanced surgically untreatable liver-
dominant (unresectable) mCRC are not amenable to 
local parenchymal tumor destruction therapy of CRCLM 
(5,35). These patients are usually treated with systemic 
chemotherapy (with or without biologic agents). Many 
patients eventually become unresponsive to chemotherapy 
(chemotherapy refractory) or are unable to tolerate multiple 
cycles of chemotherapy (chemotherapy intolerant) (36). 
Patients with advanced mCRC who have progressed 
after standard first- and second-line therapies have limited 
treatment options (36). The aim of third-line treatments is 
to prolong life, improve symptoms, and maintain quality 
of life; and disease management is often restricted to best 
supportive care with palliative intent (6,36). The goal of 
care centers on less-intensive treatments and focuses on 
disease palliation and monitoring (5,35). Control of liver 
disease is critical to ameliorating clinical outcomes, and 
subsequently, the length and quality of life (16,35,68).
The treatment of patients with advanced surgically 
untreatable liver-dominant (unresectable) mCRC is outlined 
in Figure 7 (5,14,18,25,28,31,35,61). Patients with advanced 
surgically untreatable liver-dominant disease should be started 
on systemic chemotherapy with or without biologics (5,35). 
Radiographic reassessment must be performed after 
chemotherapy to assess response (5,35). If response occurs, 
patients should be reassessed for surgical eligibility; if adequate 
FLR is achieved for clearance, a staged local parenchymal 
tumor destruction therapy may be indicated (5,35). If disease 
remains liver-dominant and surgically untreatable, SIRT with 
Y-90 followed by systemic chemotherapy or chemotherapy 
only of the whole liver can be considered (18,35). 
The expert panelists agreed that patients should be 
switched to next-line chemotherapy with or without 
biologics if disease progresses with standard systemic 
chemotherapy, with SIRT with Y-90 as an option in cases 
of chemotherapy resistance (5,18,35). If disease progresses 
with next-line therapy, SIRT with Y-90 followed by systemic 
chemotherapy or chemotherapy only of the whole liver is an 
option (5,18,35). If disease is diffuse, chemotherapy should 
be continued with or without biologics, maintaining the 
option for future treatment (5,35). For patients who truly 
have surgically untreatable liver-dominant disease, and 
who may never be candidates for local parenchymal tumor 
destruction therapy, whole-liver treatment with Y-90 is a 
possible strategy (5,18,25,35,48). 
SIRT with Y-90 has been recommended for use as an 
alternative therapy in the treatment of chemotherapy-
resistant/-refractory patients with liver-dominant mCRC 
(5,36). It may be used for local control in patients with 
liver-dominant disease that remains surgically untreatable 
after second-line chemotherapy, with the goal of improving 
liver PFS (i.e., patients who are intolerant to chemotherapy 
or who need a chemotherapy holiday) (5,18,31,35,36,48,61). 
Addi t iona l ly,  SIRT wi th  Y-90  may  be  used  as  a 
chemotherapy-sparing or time-delaying strategy in patients 
with small-volume disease that is no longer detectable after 
chemotherapy, with the goal of allowing the disease to 
reappear for the purpose of further analysis (35). 
SIRT with Y-90 has been used as salvage therapy for 
patients with diffuse liver-dominant disease that has failed 
to respond to multiple treatments (5,6,18,25,31,61). In a 
phase III RCT, Hendlisz and colleagues provided Level 1 
evidence for the survival benefit of SIRT with Y-90 (8,31). 
In the study, 44 patients heavily pretreated for unresectable 
liver-limited mCRC received either infusional 5-FU alone 
or Y-90 with concomitant infusional 5-FU (31). SIRT with 
Y-90 significantly prolonged liver tumor growth control 
(both local and overall disease progression) over protracted 
intravenous FU treatments alone and did not increase the 
toxicity of FU (31). Consideration for SIRT with Y-90 should 
be given as the patient progresses through the algorithm, 
with the concept that chemotherapy can be hepatotoxic, and 
SIRT with Y-90 should be introduced for liver control before 
the liver has been damaged severely by chemotherapy (9,35).
Discussion
Through a comprehensive, data-driven modified Delphi 
consensus model, this multidisciplinary work presents 
the first described treatment algorithm for CRCLM 
that incorporates SIRT with Y-90 and provides novel 
definitions for CRCLM disease categories based on surgical 
eligibility. The resectable, borderline resectable, and 
unresectable mCRC disease categories are clearly defined 
to provide a standardized surgical reference framework for 
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mCRC treatment. These definitions are consistent with 
oncologic definitions for other tumor types, mirroring the 
classifications used in pancreatic cancer (42). Although 
several independent groups have attempted to articulate 
these categories (34,69), none have specifically addressed 
the diverse roles of SIRT with Y-90 in relation to other 
treatments. The proposed novel stratification method of 
surgical treatability establishes specific therapy endpoints 
to allow physicians to ultimately improve quality of care. 
Moreover, the presented algorithms allow for entry of 
patients with various tumor characteristics at different 
points of treatment with the possibility of moving laterally 
and vertically as they progress through their treatment 
pathway. The new term local parenchymal tumor destruction 
therapy is meant to start a discourse about accommodating 
treatments like ablation, resection, and future locoregional 
treatments into the schema of treatment for patients with 
mCRC.
Though SIRT with Y-90 is currently used as an end-
of-line treatment modality, it may be effective at multiple 
points in the algorithm of mCRC management (32,48,70), 
e.g., to treat small metastases completely (32), as a first-line 
therapy for hepatic CRCLM alone (35) or in combination 
with chemotherapy (71-73), in combination with second- 
or third-line chemotherapy (26), and as salvage therapy for 
chemotherapy-refractory patients (25,74,75). In addition, 
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Figure 7 Treatment algorithm for patients with advanced surgically untreatable liver-dominant (unresectable) metastatic colorectal cancer 
(mCRC). ALPPS, associating liver partition and portal vein ligation for staged hepatectomy; ESMO, European Society for Medical 
Oncology; FLR, future liver remnant; HAI, hepatic artery infusion; PVE, portal vein embolization; RCTs, randomized controlled trials; 
SIRT, selective internal radiation therapy.
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SIRT with Y-90 can be used as a part of clinical strategies 
such as control of local liver progression, induction of 
contralateral hypertrophy, or treatment of the whole liver 
(18,35). These studies demonstrate that SIRT with Y-90 is 
able to prolong intrahepatic disease control and improve 
OS in specific clinical situations (24). The comprehensive 
treatment algorithm in liver-dominant mCRC shared 
here includes opportunities where SIRT with Y-90 may be 
considered and is supported by available clinical data.
When contemplating therapies, practitioners must first 
consider a comprehensive multimodal treatment plan while 
also recognizing temporal factors. For example, contralateral 
hypertrophy after SIRT with Y-90 develops at a slower 
pace (3–12 months) than after PVE (6 weeks) (18,59,65). 
These differences may allow for these 2 procedures 
to be used to achieve different treatment goals (10), 
such as immediate resection after hypertrophy (5) or to 
allow a longer interval to surgery to assess for previously 
undetected metastases (65). 
In addition, selecting appropriate patients suited to 
SIRT with Y-90 is certainly the key to treatment success 
(6,10). Patients more likely to benefit from SIRT with Y-90 
may include those with no extrahepatic metastases, fewer 
than 6 tumors, and a tumor-to-liver volume percentage of 
less than 25% (6,76). Conversely, patients with extensive 
tumor volume, more previous lines of chemotherapy, poor 
radiological response, low preoperative hemoglobin, higher 
carcinoembryonic antigen and/or cancer antigen 19-9 levels 
(30,76), KRAS mutations (77), and poor preoperative 
liver function may show poorer response to treatment 
(78,79). More investigation regarding these predictors of 
response is warranted. Appropriate patient selection and 
coordination of care may require management by a diverse 
treatment team (including hepatologists, oncologists, HPB 
surgeons, radiologists, interventional radiologists, radiation 
oncologists, nuclear medicine physicians, and nurses) (9,36). 
Especially challenging patients may benefit from review 
by a dedicated multidisciplinary tumor board, such as the 
method employed by the REsect study in which patient 
scans were reviewed for resectability of liver metastases by 
3−5 blinded expert surgeons (from a panel of 15). In that 
study, resectability was deemed when 60% of reviewers 
assessed a patient as having resectable disease, which is a 
way of ensuring treatment consistency (14). Assessment of 
patients by a multidisciplinary team that includes qualified 
HPB surgeons may expedite the process of diagnosis and 
decision-making in the management of patients in different 
surgical eligibility categories, ultimately optimizing the 
treatment pathway for each patient (4,9). 
Though there is general agreement about the sequencing 
of chemotherapeutic treatments in first- and subsequent-
line treatment for mCRC (11), it is not yet clear how to 
optimally sequence systemic treatments and locoregional 
therapies (80). Ablation after SIRT with Y-90 in heavily 
pretreated patients has been shown to be possible. In some 
patients, SIRT is able to downsize liver metastases to enable 
subsequent ablation therapy, allowing more patients to have 
a complete response after minimally invasive therapy (59). 
How different locoregional treatments and other emerging 
technologies fit into the overarching schema, as well as 
how they can be optimally combined and sequenced for 
treatment of patients with mCRC, is still unclear (80). 
Although SIRT with Y-90 may result in improved tumor 
response rates and OS, treatment must balance the desire 
for life prolongation and quality of life with the hazards of 
aggressive treatments, such as the manifestations of long-
term hepatotoxicity from Y-90 (30,81). SIRT with Y-90 
is generally well tolerated with limited liver toxicity, and 
most patients have no or mild procedure-related symptoms 
(48,82). However, if a significant number of radioactive 
particles reaches non-targeted organs such as the lung, 
the gastrointestinal tract, or the gallbladder, radiation 
exposure may lead to future complications (82). Radiation 
to the liver can produce liver injury and fibrosis secondary 
to radiation-induced fibrotic tissue remodeling, which 
results in increased portal pressures and enlargement of the 
spleen (81,83). Several studies have noted the presence of 
Y-90–induced liver fibrosis with corresponding changes in 
hepatic volumes and portal hypertension after treatment 
(83,84). Furthermore, as SIRT with Y-90 is administered to 
patients who have typically received systemic anti-cancer 
therapies as a concurrent or subsequent therapy, drug-drug 
interactions and toxicities are expected, such as radiation 
sensitization, or enhancement of expected SIRT with Y-90–
related adverse events (48). However, although the long-
term effects of Y-90 treatment on hepatic function should 
be recognized, appropriately timed treatment with SIRT 
with Y-90 may be able to mitigate some of the toxic effects 
of chemotherapy on the underlying liver parenchyma, 
potentially minimizing overall liver damage (9,35).
Although it is solidly based on a foundation of published 
clinical evidence, this work remains a descriptive analysis 
founded on the opinions and experiences of selected expert 
panelists and does not represent a uniform consensus. Also, 
as SIRT that utilizes resin microspheres is currently the 
only SIRT modality that has an FDA-approved indication 
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for treatment of CRCLM, many of the data supporting the 
algorithm were drawn from studies examining this treatment. 
Worthy of mention as well are investigations of interest that 
explore the use of SIRT with glass microspheres in treating 
CRCLM (85-87), The current algorithm does not stipulate 
the role of specific chemotherapies at different decision 
steps, and it is meant to be a more general interdisciplinary 
map of possible appropriate treatment decisions. While 
individual steps for treatment at different disease stages are 
mentioned within established guidelines, this work is the first 
to put them together in a cohesive, overarching treatment 
algorithm. Conversations stimulated by these ideas should 
pave the way for more concrete recommendations by larger 
organizations in the future.
Conclusions
SIRT with Y-90 has the potential to play a major role in 
all phases of liver mCRC treatment. This work addresses 
the need to establish standard practices for locoregional 
therapies in the treatment of patients with mCRC and 
attempts to delineate the distinct roles of SIRT with Y-90 
in patients at different stages of disease—not only in the 
palliative setting. Development of this algorithm was the 
result of a multidisciplinary effort to establish a reference 
framework for the treatment of patients with mCRC that 
incorporates SIRT with Y-90 and introduces treatment 
algorithms for 3 distinct disease categories stratified by 
surgical eligibility. This novel stratification method of 
surgical treatability establishes specific therapy endpoints to 
allow physicians to ultimately improve quality of care. 
Acknowledgments
The authors thank Ellen Hagopian, MD, Michael House, 
MD, Christopher Sonnenday, MD, Robert Martin, MD, 
Patricio Polanco, MD, Hong Jin Kim, MD, Horacio Asbun, 
MD, Nelson Royall, MD, Cristina Ferrone, MD, Sean 
Cleary, MD, William Hawkins, MD, and Shimul Shah, 
MD for their important intellectual contributions to this 
work. The authors thank Jenny Cai, MSc; Adia Shy, PhD; 
Chantal Caviness, MD, PhD; Shannon Hach, MD, ELS; 
and Edward Gloria of Eubio LLC for publication support 
for journal submission.
Funding: This work was supported by Sirtex Medical, Inc. 
Editorial assistance was provided by Eubio LLC, funded by 
Sirtex Medical, Inc. 
Footnote
Conflicts of Interest: All authors have completed the 
ICMJE uniform disclosure form (available at http://
dx.doi.org/10.21037/jgo.2020.01.09). Authors received an 
honorarium for Advisory Board attendance that served as the 
basis for the modified Delphi consensus exercise. No payment 
was provided for the time spent authoring this manuscript. 
DR Jeyarajah, NJ Espat, BC Visser, DA Iannitti, Doyle MBM, 
J Kim, and T Thambi-Pillai are or have been consultants to 
Sirtex Medical, Inc. NJ Espat has served as a speaker on behalf 
of Sirtex. DR Jeyarajah has served as a consultant to Ethicon. 
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work were 
appropriately investigated and resolved. 
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and 
the original work is properly cited (including links to both 




1. Zampino MG, Magni E, Ravenda PS, et al. Treatments 
for colorectal liver metastases: a new focus on a familiar 
concept. Crit Rev Oncol Hematol 2016;108:154-63.
2. Hugen N, van de Velde CJ, de Wilt JH, et al. Metastatic 
pattern in colorectal cancer is strongly influenced by 
histological subtype. Ann Oncol 2014;25:651-7.
3. Valderrama-Treviño AI, Barrera-Mera B, Ceballos-Villalva 
JC, et al. Hepatic metastasis from colorectal cancer. 
Euroasian J Hepatogastroenterol 2017;7:166-75.
4. Weledji EP. Centralization of liver cancer surgery and 
impact on multidisciplinary teams working on stage IV 
colorectal cancer. Oncol Rev 2017;11:331.
5. Network NCC. Clinical practice guidelines in oncology. 
Colon cancer. Version 4. 2018. 
6. White J, Carolan-Rees G, Dale M, et al. Analysis of a 
national programme for selective internal radiation therapy 
457Journal of Gastrointestinal Oncology, Vol 11, No 2 April 2020
© Journal of Gastrointestinal Oncology. All rights reserved.   J Gastrointest Oncol 2020;11(2):443-460 | http://dx.doi.org/10.21037/jgo.2020.01.09
for colorectal cancer liver metastases. Clin Oncol (R Coll 
Radiol) 2019;31:58-66.
7. Folprecht G, Gruenberger T, Bechstein WO, et al. 
Tumour response and secondary resectability of colorectal 
liver metastases following neoadjuvant chemotherapy with 
cetuximab: the CELIM randomised phase 2 trial. Lancet 
Oncol 2010;11:38-47.
8. Levy J, Zuckerman J, Garfinkle R, et al. Intra-arterial 
therapies for unresectable and chemorefractory colorectal 
cancer liver metastases: a systematic review and meta-
analysis. HPB (Oxford) 2018;20:905-15.
9. Alberts SR. Update on the optimal management of 
patients with colorectal liver metastases. Crit Rev Oncol 
Hematol 2012;84:59-70.
10. Sag AA, Selcukbiricik F, Mandel NM. Evidence-based 
medical oncology and interventional radiology paradigms 
for liver-dominant colorectal cancer metastases. World J 
Gastroenterol 2016;22:3127-49.
11. Modest DP, Pant S, Sartore-Bianchi A. Treatment 
sequencing in metastatic colorectal cancer. Eur J Cancer 
2019;109:70-83.
12. Folprecht G, Gruenberger T, Bechstein W, et al. Survival 
of patients with initially unresectable colorectal liver 
metastases treated with FOLFOX/cetuximab or FOLFIRI/
cetuximab in a multidisciplinary concept (CELIM study). 
Ann Oncol 2014;25:1018-25.
13. Young AL, Adair R, Culverwell A, et al. Variation in 
referral practice for patients with colorectal cancer liver 
metastases. Br J Surg 2013;100:1627-32.
14. Garlipp B, Gibbs P, van Hazel GA, et al. REsect: 
Blinded assessment of amenability to potentially curative 
treatment of previously unresectable colorectal cancer 
liver metastases (CRC LM) after chemotherapy ± 
radioembolization (SIRT) in the randomized SIRFLOX 
trial. J Clin Oncol 2017;35:3532.
15. Winter H, Rassam J, Virdee PS, et al. Hepatic resection 
following selective internal radiation therapy for colorectal 
cancer metastases in the FOXFIRE clinical trial: clinical 
outcomes and distribution of microspheres. Cancers (Basel) 
2019;11;1155.
16. van Hazel GA, Heinemann V, Sharma NK, et al. 
SIRFLOX: randomized phase III trial comparing first-
line mFOLFOX6 (plus or minus bevacizumab) versus 
mFOLFOX6 (plus or minus bevacizumab) plus selective 
internal radiation therapy in patients with metastatic 
colorectal cancer. J Clin Oncol 2016;34:1723-31.
17. Jones RP, Poston GJ. Resection of liver metastases in 
colorectal cancer in the era of expanding systemic therapy. 
Annu Rev Med 2017;68:183-96.
18. Abdalla EK, Bauer TW, Chun YS, et al. Locoregional 
surgical and interventional therapies for advanced 
colorectal cancer liver metastases: expert consensus 
statements. HPB (Oxford) 2013;15:119-30.
19. Ackerman NB. The blood supply of experimental liver 
metastases. IV. Changes in vascularity with increasing 
tumor growth. Surgery. 1974;75:589-96.
20. Ensminger WD, Rosowsky A, Raso V, et al. A clinical-
pharmacological evaluation of hepatic arterial infusions of 
5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res 
1978;38:3784-92.
21. Sofocleous CT, Violari EG, Sotirchos VS, et al. 
Radioembolization as a salvage therapy for heavily 
pretreated patients with colorectal cancer liver metastases: 
factors that affect outcomes. Clin Colorectal Cancer 
2015;14:296-305.
22. Mahnken AH. Current status of transarterial 
radioembolization. World J Radiol 2016;8:449-59.
23. Abdel-Rahman O, Cheung WY. Integrating systemic 
therapies into the multimodality treatment of resectable 
colorectal liver metastases. Gastroenterol Res Pract 
2018;2018:4326082.
24. Justinger C, Gruden J, Kouladouros K, et al. 
Histopathological changes resulting from selective internal 
radiotherapy (SIRT). J Surg Oncol 2018;117:1084-91.
25. Cosimelli M, Golfieri R, Cagol PP, et al. Multi-centre 
phase II clinical trial of yttrium-90 resin microspheres 
alone in unresectable, chemotherapy refractory colorectal 
liver metastases. Br J Cancer 2010;103:324-31.
26. Lim L, Gibbs P, Yip D, et al. A prospective evaluation of 
treatment with selective internal radiation therapy (SIR-
spheres) in patients with unresectable liver metastases 
from colorectal cancer previously treated with 5-FU based 
chemotherapy. BMC Cancer 2005;5:132.
27. Garlipp B, Gibbs P, Van Hazel GA, et al. Secondary 
technical resectability of colorectal cancer liver metastases 
after chemotherapy with or without selective internal 
radiotherapy in the randomized SIRFLOX trial. Br J Surg 
2019;106:1837-46.
28. Baltatzis M, Siriwardena AK. Liver resection for colorectal 
hepatic metastases after systemic chemotherapy and selective 
internal radiation therapy with yttrium-90 microspheres: a 
systematic review. Dig Surg 2019;36:273-80.
29. Sharma RA, Van Hazel GA, Morgan B, et al. 
Radioembolization of liver metastases from colorectal 
cancer using yttrium-90 microspheres with concomitant 
systemic oxaliplatin, fluorouracil, and leucovorin 
458 Jeyarajah et al. Treatment algorithm for SIRT with Y-90 in mCRC
© Journal of Gastrointestinal Oncology. All rights reserved.   J Gastrointest Oncol 2020;11(2):443-460 | http://dx.doi.org/10.21037/jgo.2020.01.09
chemotherapy. J Clin Oncol 2007;25:1099-106.
30. Damm R, Seidensticker R, Ulrich G, et al. Y90 
Radioembolization in chemo-refractory metastastic, liver 
dominant colorectal cancer patients: outcome assessment 
applying a predictive scoring system. BMC Cancer 
2016;16:509.
31. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase 
III trial comparing protracted intravenous fluorouracil 
infusion alone or with yttrium-90 resin microspheres 
radioembolization for liver-limited metastatic colorectal 
cancer refractory to standard chemotherapy. J Clin Oncol 
2010;28:3687-94.
32. Garrean S, Muhs A, Bui JT, et al. Complete eradication 
of hepatic metastasis from colorectal cancer by yttrium-90 
SIRT. World J Gastroenterol 2007;13:3016-9.
33. Chow FC, Chok KS. Colorectal liver metastases: an 
update on multidisciplinary approach. World J Hepatol 
2019;11:150-72.
34. Vera R, González-Flores E, Rubio C, et al. 
Multidisciplinary management of liver metastases in 
patients with colorectal cancer: a consensus of SEOM, 
AEC, SEOR, SERVEI, and SEMNIM. Clin Transl Oncol 
2020;22:647-62.
35. Van Cutsem E, Cervantes A, Adam R, et al. ESMO 
consensus guidelines for the management of patients with 
metastatic colorectal cancer. Ann Oncol 2016;27:1386-422.
36. Aranda E, Aparicio J, Bilbao JI, et al. Recommendations 
for SIR-Spheres Y-90 resin microspheres in chemotherapy-
refractory/intolerant colorectal liver metastases. Future 
Oncol 2017;13:2065-82.
37. Grimes M, Wright, G. Delphi Method. Wiley 
StatsRef: Statistics Reference Online 2016. doi: 
10.1002/9781118445112.stat07879. 
38. Levels of Evidence (March 2009). Oxford: Oxford Centre 
for Evidence-based Medicine; 2019. Accessed December 
20, 2019. Available online: https://www.cebm.net/2009/06/
oxford-centre-evidence-based-medicine-levels-evidence-
march-2009/ 
39. Solbiati L, Ahmed M, Cova L, et al. Small liver colorectal 
metastases treated with percutaneous radiofrequency 
ablation: local response rate and long-term survival with 
up to 10-year follow-up. Radiology 2012;265:958-68.
40. Shady W, Petre EN, Gonen M, et al. Percutaneous 
radiofrequency ablation of colorectal cancer liver 
metastases: factors affecting outcomes--a 10-year 
experience at a single center. Radiology 2016;278:601-11.
41. Wang LJ, Zhang ZY, Yan XL, et al. Radiofrequency 
ablation versus resection for technically resectable 
colorectal liver metastasis: a propensity score analysis. 
World J Surg Oncol 2018;16:207.
42. Soloff EV, Zaheer A, Meier J, et al. Staging of pancreatic 
cancer: resectable, borderline resectable, and unresectable 
disease. Abdom Radiol (NY) 2018;43:301-13.
43. Salvatore L, Aprile G, Arnoldi E, et al. Management of 
metastatic colorectal cancer patients: guidelines of the 
Italian Medical Oncology Association (AIOM). ESMO 
Open 2017;2:e000147.
44. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical 
margin status on survival and site of recurrence after 
hepatic resection for colorectal metastases. Ann Surg 
2005;241:715-22, discussion 722-4.
45. Patel S, Cheek S, Osman H, et al. MRI with gadoxetate 
disodium for colorectal liver metastasis: is it the new 
"imaging modality of choice"? J Gastrointest Surg 
2014;18:2130-5.
46. Fernández Moro C, Bozóky B, Gerling M. Growth 
patterns of colorectal cancer liver metastases and their 
impact on prognosis: a systematic review. BMJ Open 
Gastroenterol 2018;5:e000217.
47. Cortesi E, Masi, G, Mancini ML, et al. Radioembolization 
(SIRT) as a consolidation treatment in colorectal liver 
metastases after first line chemotherapy. J Clin Oncol 
2016;34:e15007.
48. Kennedy A, Brown DB, Feilchenfeldt J, et al. Safety of 
selective internal radiation therapy (SIRT) with yttrium-90 
microspheres combined with systemic anticancer agents: 
expert consensus. J Gastrointest Oncol 2017;8:1079-99.
49. Pini S, Pinto C, Angelelli B, et al. Multimodal sequential 
approach in colorectal cancer liver metastases: hepatic 
resection after yttrium-90 selective internal radiation 
therapy and cetuximab rescue treatment. Tumori 
2010;96:157-9.
50. O'Leary C, Greally M, McCaffrey J, et al. Single-
institution experience with selective internal radiation 
therapy (SIRT) for the treatment of unresectable colorectal 
liver metastases. Ir J Med Sci 2019;188:43-53.
51. Wasan HS, Gibbs P, Sharma NK, et al. First-line 
selective internal radiotherapy plus chemotherapy versus 
chemotherapy alone in patients with liver metastases from 
colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-
Global): a combined analysis of three multicentre, 
randomised, phase 3 trials. Lancet Oncol 2017;18:1159-71.
52. Cucchetti A, Cappelli A, Ercolani G, et al. Selective 
internal radiation therapy (SIRT) as conversion therapy 
for unresectable primary liver malignancies. Liver Cancer 
2016;5:303-11.
459Journal of Gastrointestinal Oncology, Vol 11, No 2 April 2020
© Journal of Gastrointestinal Oncology. All rights reserved.   J Gastrointest Oncol 2020;11(2):443-460 | http://dx.doi.org/10.21037/jgo.2020.01.09
53. Pardo F, Sangro B, Lee RC, et al. The Post-SIR-Spheres 
Surgery Study (P4S): Retrospective analysis of safety 
following hepatic resection or transplantation in patients 
previously treated with selective internal radiation therapy 
with yttrium-90 resin microspheres. Ann Surg Oncol 
2017;24:2465-73.
54. Garlipp B, de Baere T, Damm R, et al. Left-liver 
hypertrophy after therapeutic right-liver radioembolization 
is substantial but less than after portal vein embolization. 
Hepatology 2014;59:1864-73.
55. Shah JL, Zendejas-Ruiz IR, Thornton LM, et al. 
Neoadjuvant transarterial radiation lobectomy for 
colorectal hepatic metastases: a small cohort analysis 
on safety, efficacy, and radiopathologic correlation. J 
Gastrointest Oncol 2017;8:E43-51.
56. Vouche M, Lewandowski RJ, Atassi R, et al. Radiation 
lobectomy: time-dependent analysis of future liver 
remnant volume in unresectable liver cancer as a bridge to 
resection. J Hepatol 2013;59:1029-36.
57. Vivarelli M, Vincenzi P, Montalti R, et al. ALPPS 
procedure for extended liver resections: a single 
centre experience and a systematic review. PLoS One 
2015;10:e0144019.
58. Moir JA, Burns J, Barnes J, et al. Selective internal 
radiation therapy for liver malignancies. Br J Surg 
2015;102:1533-40.
59. Hoffmann RT, Jakobs TF, Kubisch CH, et al. 
Radiofrequency ablation after selective internal radiation 
therapy with yttrium90 microspheres in metastatic liver 
disease-is it feasible? Eur J Radiol 2010;74:199-205.
60. Wright GP, Marsh JW, Varma MK, et al. Liver resection 
after selective internal radiation therapy with yttrium-90 
is safe and feasible: a bi-institutional analysis. Ann Surg 
Oncol 2017;24:906-13.
61. Golfieri R, Mosconi C, Giampalma E, et al. Selective 
transarterial radioembolisation of unresectable liver-
dominant colorectal cancer refractory to chemotherapy. 
Radiol Med 2015;120:767-76.
62. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right 
portal vein ligation combined with in situ splitting induces 
rapid left lateral liver lobe hypertrophy enabling 2-staged 
extended right hepatic resection in small-for-size settings. 
Ann Surg 2012;255:405-14.
63. Schnitzbauer AA. A comparison of pitfalls after ALPPS 
stage 1 or portal vein embolization in small-for-size setting 
hepatectomies. Visc Med 2017;33:435-41.
64. Clark ME, Smith RR. Liver-directed therapies in 
metastatic colorectal cancer. J Gastrointest Oncol 
2014;5:374-87.
65. Braat MN, Samim M, van den Bosch MA, Lam MG. The 
role of (90)Y-radioembolization in downstaging primary 
and secondary hepatic malignancies: a systematic review. 
Clin Transl Imaging 2016;4:283-95.
66. Cortesi E, Masi G, Mancini M, et al. Radioembolization 
(SIRT) as a consolidation treatment in colorectal liver 
metastases after first line chemotherapy: efficacy safety. 
P-158. Ann Oncol 2016;27:ii47.
67. Benoist S, Brouquet A, Penna C, Julie C, et al. Complete 
response of colorectal liver metastases after chemotherapy: 
does it mean cure? J Clin Oncol 2006;24:3939-45.
68. Li L, Yeo W. Value of quality of life analysis in liver cancer: 
A clinician's perspective. World J Hepatol 2017;9:867-83.
69. Cetin B, Bilgetekin I, Cengiz M, et al. Managing 
synchronous liver metastases in colorectal cancer. Indian J 
Surg Oncol 2018;9:461-71.
70. Braat AJ, Huijbregts JE, Molenaar IQ, et al. Hepatic 
radioembolization as a bridge to liver surgery. Front Oncol 
2014;4:199.
71. Gray B, Van Hazel G, Hope M, et al. Randomised trial of 
SIR-Spheres plus chemotherapy vs. chemotherapy alone 
for treating patients with liver metastases from primary 
large bowel cancer. Ann Oncol 2001;12:1711-20.
72. Kosmider S, Tan TH, Yip D, et al. Radioembolization 
in combination with systemic chemotherapy as first-line 
therapy for liver metastases from colorectal cancer. J Vasc 
Interv Radiol 2011;22:780-6.
73. Sharma N, van Hazel G, Findlay M, et al. Using data from 
the SIRFLOX study to evaluate depth of response within 
a volumetric model in patients with metastatic colorectal 
cancer. J Vasc Interv Radiol 2017;28:S160-1.
74. Bester L, Meteling B, Pocock N, et al. Radioembolisation 
with yttrium-90 microspheres: an effective treatment 
modality for unresectable liver metastases. J Med Imaging 
Radiat Oncol 2013;57:72-80.
75. Kennedy AS, Ball D, Cohen SJ, et al. Multicenter 
evaluation of the safety and efficacy of radioembolization 
in patients with unresectable colorectal liver metastases 
selected as candidates for (90)Y resin microspheres. J 
Gastrointest Oncol 2015;6:134-42.
76. Kurilova I, Beets-Tan RGH, Flynn J, et al. Factors 
affecting oncologic outcomes of 90Y radioembolization 
of heavily pre-treated patients with colon cancer liver 
metastases. Clin Colorectal Cancer 2019;18:8-18.
77. Lahti SJ, Xing M, Zhang D, et al. KRAS status as an 
independent prognostic factor for survival after yttrium-90 
radioembolization therapy for unresectable colorectal cancer 
460 Jeyarajah et al. Treatment algorithm for SIRT with Y-90 in mCRC
© Journal of Gastrointestinal Oncology. All rights reserved.   J Gastrointest Oncol 2020;11(2):443-460 | http://dx.doi.org/10.21037/jgo.2020.01.09
liver metastases. J Vasc Interv Radiol 2015;26:1102-11.
78. Saxena A, Meteling B, Kapoor J, et al. Is yttrium-90 
radioembolization a viable treatment option for 
unresectable, chemorefractory colorectal cancer liver 
metastases? A large single-center experience of 302 
patients. Ann Surg Oncol 2015;22:794-802.
79. Kennedy A, Cohn M, Coldwell DM, et al. Updated survival 
outcomes and analysis of long-term survivors from the 
MORE study on safety and efficacy of radioembolization in 
patients with unresectable colorectal cancer liver metastases. 
J Gastrointest Oncol 2017;8:614-24.
80. Memon K, Kulik L, Lewandowski RJ, et al. 
Radioembolization for hepatocellular carcinoma with 
portal vein thrombosis: impact of liver function on 
systemic treatment options at disease progression. J 
Hepatol 2013;58:73-80.
81. Su YK, Mackey RV, Riaz A, et al. Long-term hepatotoxicity 
of yttrium-90 radioembolization as treatment of metastatic 
neuroendocrine tumor to the liver. J Vasc Interv Radiol 
2017;28:1520-6.
82. Sangro B, Martínez-Urbistondo D, Bester L, et al. 
Prevention and treatment of complications of selective 
internal radiation therapy: Expert guidance and systematic 
review. Hepatology 2017;66:969-82.
83. Jakobs TF, Saleem S, Atassi B, et al. Fibrosis, portal 
hypertension, and hepatic volume changes induced by 
intra-arterial radiotherapy with 90yttrium microspheres. 
Dig Dis Sci 2008;53:2556-63.
84. Maker AV, August C, Maker VK, et al. Hepatectomy after 
yttrium-90 (Y90) radioembolization-induced liver fibrosis. 
J Gastrointest Surg 2016;20:869-70.
85. Abbott AM, Kim R, Hoffe SE, et al. Outcomes of 
Therasphere radioembolization for colorectal metastases. 
Clin Colorectal Cancer 2015;14:146-53.
86. Hickey R, Lewandowski RJ, Prudhomme T, et al. 90Y 
radioembolization of colorectal hepatic metastases using 
glass microspheres: safety and survival outcomes from a 
531-patient multicenter study. J Nucl Med 2016;57:665-71.
87. Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y 
microsphere (TheraSphere) treatment for unresectable 
colorectal cancer metastases of the liver: response to 
treatment at targeted doses of 135-150 Gy as measured by 
[18F]fluorodeoxyglucose positron emission tomography 
and computed tomographic imaging. J Vasc Interv Radiol 
2005;16:1641-51.
Cite this article as: Jeyarajah DR, Doyle MBM, Espat NJ, 
Hansen PD, Iannitti DA, Kim J, Thambi-Pillai T, Visser BC. 
Role of yttrium-90 selective internal radiation therapy in the 
treatment of liver-dominant metastatic colorectal cancer: an 
evidence-based expert consensus algorithm. J Gastrointest 
Oncol 2020;11(2):443-460. doi: 10.21037/jgo.2020.01.09
